Lauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares of the company's stock, valued at approximately $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Pacira BioSciences Stock Performance

Shares of NASDAQ:PCRX traded down $0.77 on Friday, hitting $25.97. 431,551 shares of the company were exchanged, compared to its average volume of 972,803. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $29.95. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $1.20 billion, a P/E ratio of -12.79 and a beta of 0.56. The stock's 50 day moving average price is $25.49 and its 200 day moving average price is $23.26.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in Pacira BioSciences by 0.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock worth $37,541,000 after buying an additional 13,604 shares in the last quarter. Doma Perpetual Capital Management LLC raised its position in Pacira BioSciences by 3.2% during the first quarter. Doma Perpetual Capital Management LLC now owns 1,804,069 shares of the company's stock worth $44,831,000 after acquiring an additional 56,220 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Pacira BioSciences in the first quarter valued at approximately $32,506,000. Goldman Sachs Group Inc. grew its holdings in Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock valued at $27,454,000 after purchasing an additional 367,869 shares during the period. Finally, Geode Capital Management LLC grew its stake in Pacira BioSciences by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after buying an additional 5,071 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Analyst Upgrades and Downgrades

PCRX has been the subject of several analyst reports. Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Needham & Company LLC lowered their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, HC Wainwright raised their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.